Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
The Journal of Experimental Medicine|October 30, 2009
REPORT OF EXPERIMENTAL WORK ON THE DILUTION METHOD OF IMMUNIZATION FROM RABIESF Cabot
Applied Optics|March 21, 2008
Radiative transfer solution for rugged and heterogeneous scene observationsC Miesch, X Briottet, Y H Kerr, et al.
Applied Optics|March 8, 2008
Monte Carlo approach for solving the radiative transfer equation over mountainous and heterogeneous areasC Miesch, X Briottet, Y H Kerr, et al.
Journal of Cardiovascular Pharmacology|May 1, 1987
Effects of metoprolol, alone and in combination with lidocaine, on ventricular fibrillation threshold: comparison with atenolol, propranolol, and pindololW M Coram, R W Olson, M E Beil, et al.
Circulation|November 1, 1993
Recombinant hirudin in patients with chronic, stable coronary artery disease. Safety, half-life, and effect on coagulation parametersP Zoldhelyi, M W Webster, V Fuster, et al.
Herz|June 1, 1981
Comparison of two radionuclide techniques for detecting disease of right and left coronary arteriesL L Johnson, C F Cabot, D M McCarthy, et al.
Journal of the American College of Cardiology|July 18, 2000
Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapyD C Sane, L V Damaraju, E J Topol, et al.
Circulation|April 1, 1998
Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial InvestigatorsD J Kereiakes, A M Lincoff, D P Miller, et al.
Lancet (London, England)|January 15, 2000
Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for StentingE J Topol, D B Mark, A M Lincoff, et al.
Circulation|January 11, 2000
Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the EPILOG randomized trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockadeA M Lincoff, D B Mark, J E Tcheng, et al.
Pageof 2